1. Discuss cell-free DNA in plasma as potential biomarker for cancer detection and monitoring
  2. Identify potential opportunities for detecting minimal residual disease in patients with non-metastatic cancer
  3. Identify relevance and fit of circulating tumor DNA analysis methods for different applications in cancer diagnostics
Session date: 
09/28/2022 - 7:20am to 8:20am CDT
United States
  • 1.00 AAPA Category 1 CME
  • 1.00 MOC: ABS Lifelong Learning & Self-Assessment Points (Part II)
    This activity meets the ABS requirements for CME and self‐assessment credit toward Part 2 of the ABS MOC program.
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
    • 1.00 Approved for AMA PRA Category 1 Credit™

Please login or register to take this course.
Discloser List CME Internal Report
Muhammed Murtaza, MD